SCHEMBL8291441

SCHEMBL8291441

CC1OCCCCCCCC[C@@H](C(=O)C(N)=O)NC(=O)[C@@H]2C3C(CN2C(=O)[C@H]1NC(=O)OC(C)(C)C)C3(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8053483 1.00 — —
SCHEMBL16349814 0.95 — —
SCHEMBL16349801 0.95 — —
SCHEMBL12607958 0.91 — —
SCHEMBL8290714 0.88 NAAA (0.32) —
SCHEMBL8290717 0.87 — —
SCHEMBL8050346 0.87 CAPN2 (0.31) —
SCHEMBL7858719 0.86 F2 (0.34) —
SCHEMBL13685052 0.86 F2 (0.34) —
SCHEMBL8290298 0.86 F2 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
WO-2005030796-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE SCHERING CORPORATION (US) 2005-04-07 — — WO disclosed
Send feedback